Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Revenue (2016 - 2025)

Zevra Therapeutics' Revenue history spans 9 years, with the latest figure at $34.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 183.89% year-over-year to $34.2 million; the TTM value through Dec 2025 reached $106.6 million, up 351.99%, while the annual FY2025 figure was $106.5 million, 351.27% up from the prior year.
  • Revenue reached $34.2 million in Q4 2025 per ZVRA's latest filing, up from $26.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $34.2 million in Q4 2025 to a low of $123000.0 in Q3 2022.
  • Average Revenue over 5 years is $10.1 million, with a median of $6.5 million recorded in 2023.
  • Peak YoY movement for Revenue: plummeted 93.74% in 2022, then soared 2253.66% in 2023.
  • A 5-year view of Revenue shows it stood at $2.6 million in 2021, then soared by 286.91% to $10.0 million in 2022, then rose by 29.33% to $12.9 million in 2023, then fell by 6.88% to $12.0 million in 2024, then skyrocketed by 183.89% to $34.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Revenue are $34.2 million (Q4 2025), $26.1 million (Q3 2025), and $25.9 million (Q2 2025).